Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Trial to Evaluate the Efficacy and Safety of WZTL-002 in Patients With Relapsed or Refractory Large B-cell Lymphoma (ENABLE-2)

NCT06486051 is registered in ClinicalTrials.gov with Malaghan Institute of Medical Research as lead sponsor.

NCT NCT06486051
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06486051 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Trial to Evaluate the Efficacy and Safety of WZTL-002 in Patients With Relapsed or Refractory Large B-cell Lymphoma (ENABLE-2)
Lead sponsor
Malaghan Institute of Medical Research
Phase
Phase 2
Overall status
Recruiting
Start date
July 12, 2024
Completion date
June 30, 2029
Enrollment
60 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma, not otherwise specified, large b-cell lymphoma, primary mediastinal large b-cell lymphoma (pmbcl), transformed non-hodgkin lymphoma